First detection of human parechovirus infection with diarrhoea, India

Itta, Krishna Chaaithanya; Ghargi, Kirti Vittal; Kalal, Shanta; Patil, Tanmayi; Roy, Subarna

doi:10.1080/23744235.2016.1218045

Cited by 4 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, even in high resource settings, the known epidemiology of infection is likely to reflect the availability of diagnostics 46 . Small case studies suggest that HPeV is an important cause of seasonal febrile illnesses in other settings but its true epidemiology in developing countries is yet to be determined 47 . ‐ 49 …”

Section: Future Directionsmentioning

confidence: 99%

Parechovirus: an important emerging infection in young infants

Britton

Jones

Macartney

et al. 2018

Medical Journal of Australia

View full text Add to dashboard Cite

Epidemics of human parechovirus (HPeV) causing disease in young children have occurred every 2 years in Australia since 2013. HPeV genotype 3 caused the epidemic from late 2017 to early 2018. Most HPeV infections cause no or mild symptoms including gastroenteritis or influenza-like illness. Characteristically, young infants present with fever, irritability and on occasions a diffuse rash ("red, hot and angry" babies). Severe disease can manifest as meningoencephalitis, seizures or sepsis-like presentations (including septic shock), or less common presentations including signs of surgical abdomen. Testing for HPeV by specific molecular tests is indicated in children younger than 6 months of age with characteristic presentations without another confirmed diagnosis including febrile illnesses with other suggestive features (eg, rash, seizures), sepsis syndromes (including shock), and suspected meningoencephalitis (which may be detected by magnetic resonance imaging only). There are no effective antiviral therapies. Treatment is primarily supportive, including management of complications. Some infants with severe HPeV infection may have adverse neurodevelopment. Follow-up by a paediatrician is recommended.

show abstract

Section: Future Directionsmentioning

confidence: 99%